Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports a corporate governance event dated March 2, 2026. The filing details the Board of Directors' approval of a special equity award for Chief Executive Officer Yvonne Greenstreet, M.D., M.B.A., effective March 2, 2026.
Key Financial Metrics and Compensation Details
The filing does not report standard financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it focuses on the valuation and terms of the executive compensation package:
- Award Type: Special performance-based equity award (Performance Share Units).
- Target Value: $18.0 million face value (based on 55,373 Target Shares at a closing price of $325.07 on the Grant Date).
- Vesting Period: Performance measured through December 31, 2029.
- Performance Thresholds: Vesting ranges from 50% to 200% of Target Shares based on the Future Average Stock Price (30-day average) in the six months prior to the Vesting Date.
- Baseline Threshold: $500 per share (approximately 54% increase over the Grant Date price). Failure to meet this results in full forfeiture.
Material Changes and Strategic Context
The filing highlights significant strategic milestones achieved under Dr. Greenstreet's leadership leading up to the award:
- Stockholder Return: Nearly 100% return generated.
- Product Launches: Launch of AMVUTTRA in multiple indications, including a landmark 2025 approval for TTR cardiomyopathy.
- Pipeline: Over 25 programs in active clinical development, including three recently initiated Phase 3 trials.
- Profitability: The Company achieved profitability in 2025, meeting its "Alnylam P 5 x25" five-year goals.
- Future Goals: The award is designed to incentivize leadership toward the new "Alnylam 2030" aspirational goals.
- Forfeiture Risk: The award is fully performance-based; if the stock price does not reach $500 during the measurement period, the award is forfeited in full.
- Termination Conditions: Voluntary termination or retirement prior to the Vesting Date results in forfeiture. Termination without Cause, resignation for Good Reason, death, or disability allows the award to remain outstanding and vest based on actual performance.
- Change in Control: Earned shares will be determined by the transaction price, subject to continued service requirements.
- Clawback Policy: The award is subject to the Company's Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation.
- Verify the specific stock price thresholds ($500, $600, $700, $800) required for partial or full vesting of the $18 million award.
- Confirm the Company's 2025 profitability status and the details of the "Alnylam 2030" strategic goals referenced in the filing.
- Review the upcoming Form 10-Q for the quarter ended March 31, 2026, which will contain the full award agreement as an exhibit.
- Monitor the stock price trajectory relative to the $325.07 grant date price to assess the likelihood of vesting.
Guidance, Risks, and Contingencies
Management Commentary: The Board views the award as a prudent tool to retain Dr. Greenstreet and ensure stability during the next phase of growth. The award aligns executive incentives with stockholders by requiring significant stock price appreciation.
Contingencies and Risks: